• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    REPAY Appoints New Chief Financial Officer

    8/11/25 4:06:00 PM ET
    $CNDT
    $FI
    $IART
    $MRK
    Real Estate
    Real Estate
    Real Estate
    Real Estate
    Get the next $CNDT alert in real time by email

    Repay Holdings Corporation (NASDAQ:RPAY) ("REPAY" or the "Company"), a leading provider of integrated payment processing solutions, today announced the appointment of Robert Houser as Chief Financial Officer of the Company, effective September 8, 2025.

    "We are extremely excited to welcome Rob to REPAY. Rob brings over a decade of divisional CFO and operational experience within the payment industry to help him contribute immediately. Rob has held key strategic roles across his career and will be a great partner in running our company," said John Morris, Co-Founder and CEO.

    Most recently, Rob served as the Group CFO of the Public Sector and Advisor at Conduent Incorporated (NASDAQ:CNDT) ("Conduent"). He previously served as Conduent's Global Head of Strategy, Corporate Development and Advisor to CEO. Prior to Conduent, Rob spent seven years at Fiserv, Inc. (NYSE:FI) holding positions as Senior Vice President, General Manager, and CFO across several divisions. Prior to Fiserv, he was the Global Head of FP&A and Investor Relations at Integra Lifesciences, Inc. (NASDAQ:IART). He previously held various finance, accounting, and strategy roles at Firmenich, Inc, Bristol-Myers Squibb Co. (NYSE:NMY), and Merck & Co Inc. (NYSE:MRK). Rob began his career as an auditor for KPMG LLP, and he earned his MBA and bachelor's degree in accounting from Rider University.

    "With Rob's appointment, interim CFO Thomas Sullivan will return to his role as Chief Accounting Officer. We are extremely grateful for Thomas's help in managing the finance organization over the past several months and the entire REPAY team for supporting the company through the CFO transition," said John Morris.

    About REPAY

    REPAY provides integrated payment processing solutions to verticals that have specific transaction processing needs. REPAY's proprietary, integrated payment technology platform reduces the complexity of electronic payments for clients, while enhancing the overall experience for consumers and businesses.

    Forward-Looking Statements

    This communication contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about REPAY's expectations with respect to the announced leadership changes. Such forward-looking statements are based upon the current beliefs and expectations of REPAY's management and are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are difficult to predict and generally beyond REPAY's control, including, without limitation, the factors described in REPAY's reports filed with the U.S. Securities and Exchange Commission. Actual results and the timing of events may differ materially from the results anticipated in these forward-looking statements. All information set forth herein speaks only as of the date hereof in the case of information about REPAY or the date of such information in the case of information.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250811411111/en/

    Investor Relations for REPAY:

    ir@repay.com



    Media Relations for REPAY:

    Kristen Hoyman

    khoyman@repay.com

    Get the next $CNDT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CNDT
    $FI
    $IART
    $MRK

    CompanyDatePrice TargetRatingAnalyst
    Merck & Company Inc.
    $MRK
    2/25/2026$142.00Outperform
    RBC Capital Mkts
    Merck & Company Inc.
    $MRK
    2/20/2026$140.00Overweight
    Barclays
    Merck & Company Inc.
    $MRK
    2/13/2026$150.00Hold → Buy
    Deutsche Bank
    Merck & Company Inc.
    $MRK
    1/8/2026$135.00Peer Perform → Outperform
    Wolfe Research
    Merck & Company Inc.
    $MRK
    12/18/2025$130.00Market Perform → Outperform
    BMO Capital Markets
    Merck & Company Inc.
    $MRK
    11/24/2025$125.00Equal Weight → Overweight
    Wells Fargo
    Merck & Company Inc.
    $MRK
    11/13/2025$105.00Sector Outperform
    Scotiabank
    Fiserv Inc.
    $FI
    11/5/2025$62.00Outperform → Neutral
    BNP Paribas Exane
    More analyst ratings

    $CNDT
    $FI
    $IART
    $MRK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Krawitz Michael E

    4 - CONDUENT Inc (0001677703) (Issuer)

    4/3/26 3:41:23 PM ET
    $CNDT
    Real Estate

    SEC Form 4 filed by Goodburn Giles Andrew

    4 - CONDUENT Inc (0001677703) (Issuer)

    4/3/26 3:35:56 PM ET
    $CNDT
    Real Estate

    SEC Form 4 filed by Abate George Joseph

    4 - CONDUENT Inc (0001677703) (Issuer)

    4/3/26 3:31:14 PM ET
    $CNDT
    Real Estate

    $CNDT
    $FI
    $IART
    $MRK
    SEC Filings

    View All

    SEC Form DEF 14A filed by Integra LifeSciences Holdings Corporation

    DEF 14A - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Filer)

    4/6/26 4:43:25 PM ET
    $IART
    Medical/Dental Instruments
    Health Care

    SEC Form DEFR14A filed by Conduent Incorporated

    DEFR14A - CONDUENT Inc (0001677703) (Filer)

    4/6/26 4:10:37 PM ET
    $CNDT
    Real Estate

    Amendment: SEC Form SCHEDULE 13D/A filed by Repay Holdings Corporation

    SCHEDULE 13D/A - Repay Holdings Corp (0001720592) (Subject)

    4/3/26 5:32:30 PM ET
    $RPAY
    Real Estate

    $CNDT
    $FI
    $IART
    $MRK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RBC Capital Mkts initiated coverage on Merck with a new price target

    RBC Capital Mkts initiated coverage of Merck with a rating of Outperform and set a new price target of $142.00

    2/25/26 7:52:46 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Merck with a new price target

    Barclays initiated coverage of Merck with a rating of Overweight and set a new price target of $140.00

    2/20/26 8:25:04 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merck upgraded by Deutsche Bank with a new price target

    Deutsche Bank upgraded Merck from Hold to Buy and set a new price target of $150.00

    2/13/26 8:35:09 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNDT
    $FI
    $IART
    $MRK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Agadi Harshavardhan V bought $182,909 worth of shares (117,099 units at $1.56) (SEC Form 4)

    4 - CONDUENT Inc (0001677703) (Issuer)

    2/23/26 5:21:51 PM ET
    $CNDT
    Real Estate

    Chief Executive Officer Agadi Harshavardhan V bought $313,720 worth of shares (220,000 units at $1.43) (SEC Form 4)

    4 - CONDUENT Inc (0001677703) (Issuer)

    2/20/26 11:36:25 AM ET
    $CNDT
    Real Estate

    Director Palau Hernandez Margarita bought $72,650 worth of shares (50,000 units at $1.45) (SEC Form 4)

    4 - CONDUENT Inc (0001677703) (Issuer)

    2/20/26 11:33:12 AM ET
    $CNDT
    Real Estate

    $CNDT
    $FI
    $IART
    $MRK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an Investigational Bispecific Tie2 Agonist/VEGF Inhibitor, for the Treatment of Neovascular Age-Related Macular Degeneration

    Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the initiation of a pivotal Phase 2b/3 trial evaluating MK-8748 (also known as Tiespectus, EYE201), a novel investigational bispecific antibody that directly activates Tie2 signaling and inhibits vascular endothelial growth factor (VEGF), for the treatment of neovascular (wet) age-related macular degeneration (NVAMD). The study, known as MALBEC, is the first trial of a broader late-phase development program for MK-8748, with a second study in NVAMD scheduled to begin this year (NCT07496567). The decision to advance into pivotal studies is based on results from the Phase 1/2a RIOJA trial (NCT06664502),

    4/2/26 6:50:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    European Commission Approves KEYTRUDA® (pembrolizumab) Plus Paclitaxel ± Bevacizumab for the Treatment of Adults With PD-L1 (CPS ≥1) Platinum-Resistant Recurrent Ovarian Carcinoma Who Have Received One or Two Prior Systemic Treatment Regimens

    The KEYTRUDA regimen is the first and only PD-1 inhibitor-based treatment approved in the European Union for these patients Approval supported by data from the Phase 3 KEYNOTE-B96 trial in which the KEYTRUDA regimen demonstrated a statistically significant improvement in progression-free and overall survival compared to placebo plus paclitaxel, with or without bevacizumab Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced that KEYTRUDA® (pembrolizumab), in combination with paclitaxel, with or without bevacizumab, is approved in the European Union (EU) for the treatment of platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal carcinoma

    4/2/26 6:45:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merck to Hold First-Quarter 2026 Sales and Earnings Conference Call April 30

    Merck (NYSE:MRK), known as MSD outside of the United States and Canada, will hold its first-quarter 2026 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on Thursday, April 30. During the call, company executives will provide an overview of Merck's performance for the quarter. Investors, journalists and the general public may access a live audio webcast of the call via this weblink. A replay of the webcast, along with the sales and earnings news release, supplemental financial disclosures and slides highlighting the results, will be available at www.merck.com. All participants may join the call by dialing (800) 369-3351 (U.S. and Canada Toll-F

    4/1/26 7:00:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNDT
    $FI
    $IART
    $MRK
    Leadership Updates

    Live Leadership Updates

    View All

    Neuronetics Appoints Dan Reuvers as President and Chief Executive Officer

    MALVERN, Pa., March 17, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM) (the "Company"), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, today announced the appointment of Dan Reuvers as the Company's next President and Chief Executive Officer, effective March 23, 2026. Mr. Reuvers will also join the Board of Directors at that time. He succeeds Keith Sullivan, who will step down as the Company's President and Chief Executive Officer on March 23, 2026 and retire on March 31, 2026 after five and a half years of leadin

    3/17/26 7:45:00 AM ET
    $IART
    $STIM
    $TCMD
    Medical/Dental Instruments
    Health Care

    Conduent Appoints Greta Van to Board of Directors

    Finance and Technology Leader Brings Decades of Experience in Audit, Controls, Risk, Compliance and Strategy Across Global Public Companies Conduent Incorporated (NASDAQ:CNDT), a global technology-driven business solutions and services company, today announced the appointment of Greta Van to its Board of Directors. Van brings more than two decades of progressive leadership experience spanning finance, audit, enterprise risk management, and strategic operations within global, publicly traded organizations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260306360053/en/Greta Van Van currently serves as Chief Audit Executive at J

    3/6/26 4:05:00 PM ET
    $CNDT
    Real Estate

    Merck Evolves Human Health Operating Structure to Support Portfolio Execution

    Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today highlighted steps to evolve the structure of its Human Health organization to ensure strong commercial execution of launches across diverse therapeutic areas, positioning the company for continued commercial success. As part of this evolution, Merck is organizing its Human Health business into an Oncology Business Unit and a Specialty, Pharma & Infectious Diseases Business Unit. This structure will enable Merck to sustain long-term leadership in oncology, while maintaining a sharp focus in support of a growing number of launches across an increasingly broad and diverse portfolio. In support of the new Human He

    2/23/26 6:45:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNDT
    $FI
    $IART
    $MRK
    Financials

    Live finance-specific insights

    View All

    Merck to Hold First-Quarter 2026 Sales and Earnings Conference Call April 30

    Merck (NYSE:MRK), known as MSD outside of the United States and Canada, will hold its first-quarter 2026 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on Thursday, April 30. During the call, company executives will provide an overview of Merck's performance for the quarter. Investors, journalists and the general public may access a live audio webcast of the call via this weblink. A replay of the webcast, along with the sales and earnings news release, supplemental financial disclosures and slides highlighting the results, will be available at www.merck.com. All participants may join the call by dialing (800) 369-3351 (U.S. and Canada Toll-F

    4/1/26 7:00:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    REPAY Announces Agreement to Acquire KUBRA

     Combination creates a Scaled Consumer Bill Payment Provider REPAY to host conference call tomorrow at 8:00 AM ET Repay Holdings Corporation (NASDAQ:RPAY) ("REPAY" or the "Company"), a leading provider of integrated payment processing solutions, today announced a definitive agreement to acquire Kubra Data Transfer LTD. ("KUBRA") for approximately $372 million. The acquisition will be financed with a combination of cash on hand and debt financing. KUBRA is a leading provider of bill payment and customer communication management solutions serving some of the largest utility and government entities, touching over 40% of households in the US and Canada. KUBRA offers an embedded technology

    3/30/26 6:00:00 PM ET
    $RPAY
    Real Estate

    REPAY Reports Fourth Quarter and Full Year 2025 Financial Results

    Strong Normalized Growth and Free Cash Flow Generation in Q4 Provides 2026 Outlook for Double-Digit Reported Revenue Growth with Free Cash Flow Repay Holdings Corporation (NASDAQ:RPAY) ("REPAY" or the "Company"), a leading provider of vertically-integrated payment solutions, today reported financial results for its fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial Highlights ($ in millions)   Q4 2024     Q1 2025     Q2 2025     Q3 2025     Q4 2025   Revenue   $ 78.3     $ 77.3     $ 75.

    3/9/26 4:05:00 PM ET
    $RPAY
    Real Estate

    $CNDT
    $FI
    $IART
    $MRK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Repay Holdings Corporation

    SC 13G - Repay Holdings Corp (0001720592) (Subject)

    11/14/24 5:17:53 PM ET
    $RPAY
    Real Estate

    Amendment: SEC Form SC 13G/A filed by Conduent Incorporated

    SC 13G/A - CONDUENT Inc (0001677703) (Subject)

    11/14/24 1:28:32 PM ET
    $CNDT
    Real Estate

    Amendment: SEC Form SC 13G/A filed by Fiserv Inc.

    SC 13G/A - FISERV INC (0000798354) (Subject)

    11/14/24 1:22:34 PM ET
    $FI
    Real Estate